1-6 of 6
Yi-Lin Chiu
Close
Sort by
Journal Articles

Phase 1 Study of ABT-348, A Dual Aurora/VEGF-Receptor Kinase Inhibitor, in Patients with Advanced Hematologic Malignancies.

Guillermo Garcia-Manero, MD, Raoul Tibes, MD, Yi-Lin Chiu, PhD, Hao Xiong, PhD, Qin Qin, Peter Ansell, PhD, Daniel H. Albert, PhD, BSc, Chris Tse, PhD, Brian Oliver, Karim Sajwani, MS, Mark D. McKee, MD, Justin L. Ricker, MD, PhD, H. Jean Khoury, MD
Journal: Blood
Blood (2012) 120 (21): 2617.
https://doi.org/10.1182/blood.V120.21.2617.2617
Published: 2012
Journal Articles

Phase 1/2a Study of ABT-263 in Relapsed or Refractory Lymphoid Malignancies.

Wyndham H Wilson, MD, PhD, Owen A O'Connor, MD, PhD, Myron S Czuczman, Ann LaCasce, MD, John Gerecitano, MD, PhD, John P. Leonard, MD, Anil Tulpule, MD, Hao Xiong, Ph.D., Yi-Lin Chiu, Todd Busman, Sari Enschede, Andrew Krivoshik, Rod Humerickhouse
Journal: Blood
Blood (2009) 114 (22): 1711.
https://doi.org/10.1182/blood.V114.22.1711.1711
Published: 2009
Journal Articles

An Ongoing Phase 1 Study of ABT-263; Pharmacokinetics, Safety and Anti-Tumor Activity in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Andrew W. Roberts, MBBS, PhD, Jennifer Brown, MD, PhD, John F. Seymour, M.D., William G. Wierda, M.D., Ph.D, Thomas J. Kipps, MD, PhD, Hao Xiong, Ph.D., Yi-Lin Chiu, PhD, Todd Busman, PhD, Raymond A. Knight, MBA, Sari Enschede, MD, Andrew Krivoshik, MD, PhD, Rod Humerickhouse, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 3177.
https://doi.org/10.1182/blood.V112.11.3177.3177
Published: 2008
Journal Articles

Pharmacokinetic Results from a Phase 1 Study of a Multi-Targeted Tyrosine Kinase Inhibitor, ABT-869, in Patients with Refractory or Relapsed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Wendy Stock, MD, Karen WL Yee, MD, Eunice S. Wang, MD, Sari Enschede, MD, Joyce Steinberg, MD, Rod Humerickhouse, MD, PhD, Qin Qin, PhD, Jiang Qian, PhD, Yi-Lin Chiu, PhD, Neeraj Gupta, PhD, Rajendra Pradhan, PhD
Journal: Blood
Blood (2008) 112 (11): 4008.
https://doi.org/10.1182/blood.V112.11.4008.4008
Published: 2008
Journal Articles

Phase 1 Study of ABT-263, a Bcl-2 Family Inhibitor, in Relapsed or Refractory Lymphoid Malignancies.

Wyndham H Wilson, MD, PhD, O. O’Connor, M.D., Myron S. Czuczman, MD, Ann LaCasce, MD, J. Gerecitano, M.D., Ph.D., John P. Leonard, MD, Anil Tulpule, MD, Hao Xiong, Ph.D., Yi-Lin Chiu, Ph.D., Todd Busman, Ph.D., Raymond A. Knight, MBA, Sari Enschede, M.D., Andrew Krivoshik, M.D., Ph.D., Rod Humerickhouse, M.D., Ph.D
Journal: Blood
Blood (2008) 112 (11): 2108.
https://doi.org/10.1182/blood.V112.11.2108.2108
Published: 2008
Journal Articles

A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects with Refractory or Relapsed Lymphoid Malignancies.

Wyndham H. Wilson, Anil Tulpule, Alexandra M. Levine, Kieron Dunleavy, Andrew P. Krivoshik, Anne E. Hagey, Margaret Shovlin, Melanie A. Gloria, Renee Greco, Hao Xiong, Yi-Lin Chiu, Steven W. Elmore, Owen A. O’Connor
Journal: Blood
Blood (2007) 110 (11): 1371.
https://doi.org/10.1182/blood.V110.11.1371.1371
Published: 2007